Emerging therapies in immunoglobulin A nephropathy

Nephrology (Carlton). 2015 Nov;20(11):788-800. doi: 10.1111/nep.12527.


Despite advances in our understanding of immunoglobulin A nephropathy (IgAN) over the past decade, there are currently no specific therapies capable of targeting key pathways involved in the pathogenesis of the disease. Recent studies have, however, provided new insights into important molecular pathways that are likely to be amenable to therapeutic manipulation in the future. Specifically, a deeper understanding of the role of mucosal immunity, B-cell activation and mesangial cell activation in IgAN has provided the impetus for a number of exciting phase II/III clinical trials in IgAN. In this review, we examine some of these on-going studies, first examining studies that clarify the role of traditional immunosuppression in IgAN, then focusing on novel therapies in early clinical studies, looking closely at the rationale for these agents in relation to our current understanding of the pathogenesis of IgAN. Finally, we examine emerging pathways and therapeutic agents that have the potential to be developed as novel therapies in the coming years. It is hoped that as we continue to develop a greater understanding of IgAN, emerging therapies will soon become a reality in the day-to-day treatment of patients with IgAN.

Trial registration: ClinicalTrials.gov NCT00498368 NCT00554502 NCT01103778 NCT01560052 NCT01738035 NCT02062684 NCT02112838.

Keywords: IgA nephropathy; clinical trial; immunosuppression; novel therapy.

Publication types

  • Clinical Trial

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Drug Discovery
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / therapeutic use*
  • Glomerulonephritis, IGA / diagnosis
  • Glomerulonephritis, IGA / drug therapy*
  • Glomerulonephritis, IGA / immunology
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Signal Transduction / drug effects
  • Treatment Outcome


  • Drugs, Investigational
  • Immunosuppressive Agents

Associated data

  • ClinicalTrials.gov/NCT00498368
  • ClinicalTrials.gov/NCT00554502
  • ClinicalTrials.gov/NCT01103778
  • ClinicalTrials.gov/NCT01560052
  • ClinicalTrials.gov/NCT01738035
  • ClinicalTrials.gov/NCT02062684
  • ClinicalTrials.gov/NCT02112838